MENS — Jyong Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $3.40bn
- $3.42bn
- 11
- 68
- 46
- 37
Annual cashflow statement for Jyong Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.92 | -4.2 | -6.63 | -4.4 | -3.02 |
| Depreciation | |||||
| Non-Cash Items | 0.803 | 0.849 | 0.599 | 0.554 | 0.761 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.084 | 1.24 | 2.94 | 1.12 | -1.49 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.09 | -1.98 | -2.97 | -2.6 | -3.62 |
| Capital Expenditures | -0.089 | -0.137 | -0.246 | 0 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.82 | -1.17 | 1.64 | 0.095 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.731 | -1.31 | 1.39 | 0.095 | 0 |
| Financing Cash Flow Items | 0.035 | -0.035 | -0.276 | -0.445 | -0.213 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.91 | -1.38 | 3.33 | 2.03 | 1.99 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.7 | -4.61 | 1.72 | -0.532 | -1.64 |